A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors.
Yongheng Liu(Kelun Group (China)), Jingyi Wang(Qingdao University), Jian Xu(University of California, Los Angeles), Qing Yan(Kelun Group (China)), Wei‐Xiang Qi(East China University of Science and Technology), Wei Lian(Kelun Group (China)), Tongtong Xue(Beijing Institute of Technology), Xi Zhao(Chongqing Medical University), Xiao Liang(Harbin Medical University)
Cited by 3
Related Papers
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
|Gastric Cancer|2014|615
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription
|Nature Communications|2019|254
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
|Pharmacology & Therapeutics|2019|245